Angus Dalgleish, MD - The Role of LDN in the Management of Cancer (2017 Conference) (LDN, low dose naltrexone)

Prof. Angus Dalgleish: Well, I'm going to talk about LDN and cancer, and I'm coming from a very different, way of doing things. I was trained in some of my research at the Institute of Cancer Research, where you basically design drugs, put them in mice.

Angus Dalgleish, MD - The role of LDN in cancer management (2019 Conference) (LDN, low dose naltrexone)

Nasha Winters, ND - Using LDN to Quell the Over-Reactive Autoimmune Conditions Triggered by Many of Today's Cancer Drugs (2019 Conference) (LDN, low dose naltrexone)

Dr Akbar Khan's LDN 2019 Conference Presentation

Low Dose Naltrexone (LDN) vs. Chemotherapy: One “Unproven” Therapy Against Another?

Stephen Dickson, BSC (hons) MRPharmS - Mechanism of Action of Low Dose Naltrexone (2019 Conference) (LDN, low dose naltrexone)

LDN 2019 Conference - Saturday Morning Q&A (2019 Conference) (LDN, low dose naltrexone)

Presentations on the below and questions were asked in relation to:

Sajad Zalzala, MD - What Patients Need to Know About Telemedicine (2019 Conference) (LDN, low dose naltrexone)

Sajad Zalzala, MD discusses what telemedicine is, its use and benefits, and about using LDN Direct telemedicine/LDN prescription business. Some telemedicine regulations are presented, as well as common conditions treated with LDN

Paul Battle, PA-C - Autoimmune Hepatitis (2019 Conference) (LDN, low dose naltrexone)

LDN 2019 Conference - Friday Morning Q&A (2019 Conference) (LDN, low dose naltrexone)

Presentations on the below and questions were asked in relation to:

Dana Keaton, ND - The scope of patient selection for LDN (2019 Conference) (LDN, low dose naltrexone)